WASHINGTON, D.C.—Challenges abound for the manufacturing of biosimilar drugs—from their sheer size compared with small molecule drugs to the unknowable proprietary aspects of the originator drugs—an expert said at the 2016 ACR/ARHP Annual Meeting in a session titled Immunology Update: Biologic Agents: From Nature to Protein Engineering to Biosimilars. Above all, because biosimilars are copies…
How to Survive MACRA
The year 2015 brought the end of the much-maligned Sustainable Growth Rate (SGR), sometimes known as the “doc fix.” The SGR established limits on Medicare reimbursement for physicians, and each year, physicians and those lobbying on their behalf were forced to stave off drastic cuts to their payments. “The SGR was Congress’s attempt to control…
ACR Leaders to Talk Policy with Congressional Leaders in D.C.
On May 11, ACR leaders will fly to Capitol Hill to meet with Congressional leaders on behalf of ACR and ARHP members. With so many pressing policy issues facing the medical community this year, we hope that you, too, will let your members of Congress know where you stand on the following issues: Support Medical…
Nevada Rheumatologists Take on Biologic and Biosimilar Substitution
On March 22, 2017, Ewa Olech, MD, testified at a hearing before the Nevada State Assembly to voice support for A.B. 245, a bill governing biologic medications and biosimilar substitution in that state. She spoke on behalf of the Rheumatology Association of Nevada (RAN), as its president and founder. The bill establishes guidelines regarding biosimilars and requires…
The ACR Agenda in D.C.: Where We Stand in Mid-April
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. Here’s a perspective on the current climate in which your government affairs team works. As you read this list of observations, imagine you’re a lawmaker and try to find where the ACR’s agenda fits into the current landscape: Washington is highly…
Ohio Rheumatologists Advocate for Step Therapy Reform & More
On a chilly March morning in Lancaster, Ohio, rheumatologist Stephanie Ott, MD, shared the Ohio Association of Rheumatology’s (OAR) current advocacy efforts with ACR@Work between walking her three dogs and driving to her clinic to see patients—some of whom travel from as far away as West Virginia. “This year, we are really focusing on legislation…
New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis
WASHINGTON, D.C.—Researchers have identified nine new genetic loci linked with juvenile idiopathic arthritis (JIA), along with evidence that at least some of them likely play a functional role, such as cytokine signaling and T cell expression. The findings were presented in an abstract session at the 2016 ACR/ARHP Annual Meeting, which also included a presentation…
Volunteers Wanted to Join the ACR’s Committees, Board of Directors, Research Foundation
In 1974, President Nixon established a week in April to recognize the importance of volunteering. National Volunteer Week is scheduled for April 23–29 this year. At the College, we like to acknowledge and thank our volunteers year round. The mission of the College cannot be achieved without the time, effort, talent and dedication of our…
How to Bill Medicare Patients for Non-Covered Services
What do you do when you are presented with a patient who needs treatment but the patient’s insurance company will not pay for the services? Can you provide the services anyway? Who will pay for them? How do you collect payment for such services? If the patient consents to receive the services in spite of…
Ethics Forum: Teach Rheumatology Fellows to Use Good Judgment in Pharmaceutical Company Interactions
We teach medical students, residents and fellows evidence-based medicine to lay the groundwork for rational prescribing and good clinical judgment. But should we stop our rheumatology fellows from interacting with pharmaceutical companies as part of this foundation? It is not surprising that pharmaceutical companies can influence physician prescribing through gifts. At least, it should not…
- « Previous Page
- 1
- …
- 158
- 159
- 160
- 161
- 162
- …
- 304
- Next Page »